Monograph
L04AB02 - Infliximab |
Propably not porphyrinogenic |
PNP |
Important Information
Patients on immunosuppressive therapy have an increased risk of infections. Since infections have a potential to trigger acute porphyric attacks vigilance is motivated regarding signs or symptoms of infection and/or possible symptoms of a porphyric attack. Side effects like nausea and vomiting may potentially be porphyrinogenic through reduction in carbohydrate intake.
Side effects
Infections are common in patients using immunosuppressants and since infections might trigger an acute porphyric attack, vigilance regarding signs and symptoms of an infection and/ or a porphyric attack is recommended. Common adverse reactions of infliximab that can be confused with an acute porphyric attack are gastrointestinal discomfort and nausea. These side effects may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Rationale
Infliximab is an antibody preparation not metabolized by CYP. No pharmacokinetic porphyrinogenic effects are suspected.
Chemical description
Infliximab is a chimeric human-murine immunoglobulin G1 kappa (IgG1 kappa) monoclonal antibody that has a high affinity for human tumor necrosis factor (TNF; TNF-alpha).
Therapeutic characteristics
Infliximab is a biologic response modifier, used in the treatment of patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis, and Crohns disease and ulcerative colitis. It is administered by intravenous infusion.
Metabolism and pharmacokinetics
Mechanisms for elimination of monoclonal antibodies are not well documented but are reported to include proteolysis by the liver and the reticuloendothelial system, target-mediated elimination and nonspecific endocytosis (Keizer 2010).
References
# | Citation details | PMID |
---|---|---|
* | Scientific articles | |
1. | Clinical pharmacokinetics of therapeutic monoclonal antibodies.
Keizer RJ, Huitema AD et al. Clin Pharmacokinet. 2010 Aug; 49 (8):493-507. |
|
* | Drug reference publications | |
2. | McEvoy GK, editor. Infliximab. The AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2009. Electronic version (31.09.10).
|
|
3. | Sweetman SC, editor. Martindale: The complete drug reference. Infliximab. Pharmaceutical Press 2009.
|
|
* | Government bodies | |
4. | European Public Assessment Report, Remicade (Scientific discussion).European Medicines Agency (EMEA). Accessible from: emea.europa.eu
|
|
* | Summary of Product Characteristics | |
5. | The electronic Medicines Compendium (eMC). Remicade. Summary of Product Characteristics (SPC).
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Flixabi · Flixabi 100 mg, poeder voor concentraat voor oplossing voor infusie · Inflectra · Inflectra 100 mg, poeder voor concentraat voor oplossing voor infusie · Remicade · Remicade 100 mg, poeder voor oplossing voor infusie · Remsima · Remsima 100 mg, poeder voor concentraat voor oplossing voor infusie · Remsima 120 mg/ml oplossing voor injectie in voorgevulde pen · Remsima 120 mg/ml oplossing voor injectie in voorgevulde spuit · Zessly · Zessly 100 mg, poeder voor concentraat voor oplossing voor infusieBelgium
Flixabi · Flixabi 100 mg sol. perf. (pdr., à diluer) i.v. flac. · Inflectra · Inflectra 100 mg sol. perf. (pdr., à diluer) i.v. flac. · Remicade · Remicade 100 mg sol. perf. (pdr., à diluer) i.v. flac. · Remsima · Remsima 100 mg sol. perf. (pdr., à diluer) i.v. flac. · Remsima 120 mg sol. inj. s.c. ser. préremplie · Remsima 120 mg sol. inj. s.c. stylo prérempli · Zessly · Zessly 100 mg sol. perf. (pdr., à diluer) i.v. flac.United Kingdom
Flixabi · Flixabi 100mg powder for concentrate for solution for infusion vials · Inflectra · Inflectra 100mg powder for concentrate for solution for infusion vials · Remicade · Remicade 100mg powder for concentrate for solution for infusion vials · Remsima · Remsima 100mg powder for concentrate for solution for infusion vials · Remsima 120mg/1ml solution for injection pre-filled pens · Remsima 120mg/1ml solution for injection pre-filled syringes · Zessly · Zessly 100mg powder for concentrate for solution for infusion vialsDenmark
Flixabi · Inflectra · Remicade · Remsima · ZesslyNorway
Flixabi · Remicade · Remsima · ZesslyPoland
Flixabi · Inflectra · Remicade · Remsima · ZesslyLuxembourg
Flixabi · Inflectra · Inflectra 10mg/ml · REMICADE · Remsima · ZesslyIceland
Flixabi · Inflectra · Remicade · Remsima · ZesslyFinland
Flixabi · Inflectra · Remicade · Remsima · ZesslyLatvia
Flixabi · Inflectra · Remicade · Remsima · ZesslySerbia
Inflectra · Inflectra® · Remicade · Remicade® · REMSIMA · REMSIMA™
© NAPOS 2024